958 related articles for article (PubMed ID: 24661086)
1. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
2. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Kang Y; Li C; Mei H
J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046
[TBL] [Abstract][Full Text] [Related]
4. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.
Anwer F; Shaukat AA; Zahid U; Husnain M; McBride A; Persky D; Lim M; Hasan N; Riaz IB
Immunotherapy; 2017 Jan; 9(2):123-130. PubMed ID: 28128714
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L; Kochenderfer JN
Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
[TBL] [Abstract][Full Text] [Related]
6. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Kochenderfer JN; Yu Z; Frasheri D; Restifo NP; Rosenberg SA
Blood; 2010 Nov; 116(19):3875-86. PubMed ID: 20631379
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity.
Chan WK; Suwannasaen D; Throm RE; Li Y; Eldridge PW; Houston J; Gray JT; Pui CH; Leung W
Leukemia; 2015 Feb; 29(2):387-95. PubMed ID: 24888271
[TBL] [Abstract][Full Text] [Related]
9. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
[TBL] [Abstract][Full Text] [Related]
10. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
12. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
Barrett DM; Grupp SA; June CH
J Immunol; 2015 Aug; 195(3):755-61. PubMed ID: 26188068
[TBL] [Abstract][Full Text] [Related]
14. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
Daher M; Rezvani K
Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
[TBL] [Abstract][Full Text] [Related]
15. Stealth transgenes enable CAR-T cells to evade host immune responses.
Grauwet K; Berger T; Kann MC; Silva H; Larson R; Leick MB; Bailey SR; Bouffard AA; Millar D; Gallagher K; Turtle CJ; Frigault MJ; Maus MV
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724463
[TBL] [Abstract][Full Text] [Related]
16. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
17. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
Kamiya T; Wong D; Png YT; Campana D
Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
[TBL] [Abstract][Full Text] [Related]
18. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
Vera J; Savoldo B; Vigouroux S; Biagi E; Pule M; Rossig C; Wu J; Heslop HE; Rooney CM; Brenner MK; Dotti G
Blood; 2006 Dec; 108(12):3890-7. PubMed ID: 16926291
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer.
Chmielewski M; Abken H
Cancer Immunol Immunother; 2012 Aug; 61(8):1269-77. PubMed ID: 22274776
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-modified T cells: CD19 and the road beyond.
Salter AI; Pont MJ; Riddell SR
Blood; 2018 Jun; 131(24):2621-2629. PubMed ID: 29728402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]